The PARP inhibitors 3-aminobenzamide (3-AB) or 5-aminoisoquinolinone (5-AIQ) reduce excessive PAR formation in the process of DNA damage repair by inhibiting the activity of PARP enzymes, thus alleviating the inflammatory response, apoptosis, and tissue damage, and, thus, have potential therapeutic effects in varied clinical entities, such as spinal cord injuries and stroke [27]. The gene discussed is PARP1; the disease is stroke disorder.